Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
06/1995
06/27/1995US5428046 Acylsulfonamido- and sulfonamidopyridine-2-carboxylic acid esters and their pyridine N-oxides, processes for their preparation and their use as medicaments
06/27/1995US5428029 Vitamin D3 fluorinated analogs
06/27/1995US5428019 Bombesin analogs
06/27/1995US5428011 Human seminal prostate inhibin in combination with anticancer drug
06/27/1995US5427925 Recombniant method for making leukemia inhibitor factor
06/27/1995CA1336119C Vinca derivative conjugates containing a c-3 detergent chain
06/27/1995CA1336076C Metal radionuclide labeled proteins for diagnosis and therapy
06/27/1995CA1336048C Process for making flexographic plates with increased flexibility
06/22/1995WO1995016707A1 ANALOGUES OF hGH-RH (1-29)NH2 HAVING ANTAGONISTIC ACTIVITY
06/22/1995WO1995016696A2 Modified oligonucleotides, method for producing them and use as active substances
06/22/1995WO1995016695A2 3'-aziridino-anthracycline derivatives
06/22/1995WO1995016694A1 Origin of replication complex genes, proteins and methods
06/22/1995WO1995016693A2 4'-o-sulfonyl-anthracycline derivatives
06/22/1995WO1995016672A1 Vitamin d amine and amide derivatives
06/22/1995WO1995016464A1 Controlled release of pharmaceutically active substances for immunotherapy
06/22/1995WO1995016437A1 Method of transmitting a biologically active material to a cell
06/22/1995WO1995015381A3 Human mutator gene hmsh2 and hereditary non polyposis colorectal cancer
06/22/1995WO1995010271A3 Phenylacetate and derivatives alone or in combination with other compounds against neoplastic conditions and other disorders
06/22/1995WO1995009241A3 Anti-cancer gene therapy by modulation of immune or inflammatory response
06/22/1995DE4407742C1 Transdermal patch for treating tumours
06/22/1995CA2178965A1 Origin of replication complex genes, proteins and methods
06/22/1995CA2178902A1 Controlled release of pharmaceutically active substances for immunotherapy
06/22/1995CA2178218A1 Analogues of hgh-rh (1-29)nh2 having antagonistic activity
06/22/1995CA2178090A1 Vitamin d amine and amide derivatives
06/22/1995CA2154890A1 3'-aziridino-anthracycline derivatives
06/22/1995CA2138501A1 Methods of inhibiting breast disorders
06/22/1995CA2138454A1 Methods of inhibiting imperfect tissue repair
06/21/1995EP0658343A1 Use of 17-beta-hydroxywortmannin and analogs thereof for phosphatidylinositol-3-kinase
06/21/1995EP0658209A1 Endothelial lineage specific transcriptional regulatory element from tek
06/21/1995EP0658159A1 Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors
06/21/1995EP0658117A1 Treatment of tumors with neurotrophic factors and cell proliferation inhibitors
06/21/1995EP0658115A1 Peptide medicaments for treating disease
06/21/1995EP0550704B1 Biotenside esters with vitamin d compounds; their preparation and transformation into spontaneously dispersible concentrates, and their use for treating tumors
06/21/1995CN1028997C Anthracycline pharmaceuticals and process for preparing same
06/20/1995US5426194 Antimitosis agent
06/20/1995US5426110 Inhibiting dihydrofolate reductase in mammals and treating susceptible reoplasms
06/20/1995US5426044 Minactivin compositions and antibodies to minactivin
06/16/1995CA2137896A1 Propynyl biaromatic compounds; pharmaceutical and cosmetic compositions containing the same and their uses
06/15/1995WO1995016051A2 Methods and compositions for the suppression of neu mediated transformation
06/15/1995WO1995015979A1 Pretargeting methods and compounds
06/15/1995WO1995015978A1 Pretargeting methods and compounds
06/15/1995WO1995015952A1 4,6-dianilino-pyrimidine derivatives, their preparation and their use as tyrosine kinase inhibitors
06/15/1995WO1995015939A1 Tricyclic derivatives, pharmaceutical compositions containing them
06/15/1995WO1995015767A1 Long-acting injection suspensions and a process for their preparation
06/15/1995WO1995015758A1 Aryl and heteroaryl quinazoline compounds which inhibit csf-1r receptor tyrosine kinase
06/15/1995WO1995015749A1 Cysteine protease inhibitors containing heterocyclic leaving groups
06/15/1995WO1995014100A3 Transcriptional regulatory sequence of carcinoembryonic antigen for expression targeting
06/15/1995WO1995012678A3 Improvements relating to cancer therapy
06/15/1995CA2178477A1 Pretargeting methods and compounds
06/15/1995CA2178476A1 Pretargeting methods and compounds
06/15/1995CA2177835A1 Methods and compositions for the suppression of neu mediated transformation
06/15/1995CA2177495A1 Cysteine protease inhibitors containing heterocyclic leaving groups
06/14/1995EP0657541A1 Novel entities for cancer therapy
06/14/1995EP0657540A1 Novel entities for cancer therapy
06/14/1995EP0657539A1 Novel entities for cancer therapy
06/14/1995EP0657536A1 Proteases capable of shedding the soluble TNF-receptor and TNF-R derived peptides and antibodies against the proteases inhibiting the shedding
06/14/1995EP0657533A1 Monoclonal antibodies with high cytotoxicity against the human CD16 antigen, and bispecific monoclonal antibodies using such monoclonal antibodies and the CD30-HRS-3 antibody
06/14/1995EP0657471A1 Anti ganglioside monoclonal antibodies and their use in the specific active immunotherapy of malignant tumours
06/14/1995EP0657468A1 Human stromae derived factor
06/14/1995EP0657467A1 Antitumor antibiotics
06/14/1995EP0657458A1 Protein kinase C inhibitors
06/14/1995EP0657175A2 Vaccine comprising autologous epidermal growth factor and use thereof
06/14/1995EP0657167A2 Use of oenotheine B for the manufacture of a medicament for the treatment of disorders related to hyperandrogenism, pharmaceutical compositions containing oenotheine B and a process for its preparation from epilobium parviflorum
06/14/1995EP0657164A1 Pharmaceutical compositions containing staurosphorine derivatives
06/14/1995EP0656946A1 Immunoglobulins devoid of light chains
06/14/1995EP0656944A1 Human melanocyte stimulating hormone receptor
06/14/1995EP0656903A1 Methods and compositions for the identification, characterization, and inhibition of farnesyltransferase
06/14/1995EP0656788A1 Hla binding peptides and their uses
06/14/1995EP0656786A1 Health supplements containing phyto-oestrogens, analogues or metabolites thereof
06/13/1995US5424464 p-[Bis(2-chloroethyl)amino]phenylalanine compounds
06/13/1995US5424416 Process for preparation of 2-deoxy-2,2-difluoro-D-ribofuranosyl-3,5-hydroxy protected-1-alkyl and aryl sulfonates and their use in preparation of 2',2'-difluoro-2'-deoxy nucleosides
06/13/1995US5424308 Immunomodulating agents
06/13/1995US5424305 Treating a cancer bladder by photosensitive a porphyrins or a chlorophylls antitumor agent
06/13/1995US5424293 Phenylimidazolidine derivatives and their use
06/13/1995US5424287 A pure protein-based extract prepared by alkaline extraction a bacterial suspension at a PH between 11 to 13; stimulants for production of prostaglandins, anticarcinogenic agents; immunology
06/13/1995US5424201 Method for preparing an antitumor dextran using Lactobacillus confusus
06/13/1995CA1335892C Saccharide derivatives
06/13/1995CA1335883C Enhancement of the cellular immune response
06/08/1995WO1995015382A1 Binding structures directed against the ca55.1 antigen
06/08/1995WO1995015381A2 HUMAN MUTATOR GENE hMSH2 AND HEREDITARY NON POLYPOSIS COLORECTAL CANCER
06/08/1995WO1995015378A1 Antisense oligonucleotides having tumorigenicity-inhibiting activity
06/08/1995WO1995015373A2 Inhibition of dna methyltransferase
06/08/1995WO1995015341A1 Antibody against carcinoembryonic antigen (cea)
06/08/1995WO1995015339A1 Antagonists to chaperonin 10
06/08/1995WO1995015338A1 Chaperonin 10
06/08/1995WO1995015336A1 Double-chain hemoregulatory peptides
06/08/1995WO1995015333A1 Nucleosides and oligonucleotides containing boron clusters
06/08/1995WO1995015311A1 Tachykinin antagonists
06/08/1995WO1995015309A1 Dp-iv-serine protease inhibitors
06/08/1995WO1995015179A1 Method of treating intestinal disorders
06/08/1995WO1995015171A1 A 46 Kd HUMAN MILK FAT GLOBULE ANTIGEN
06/08/1995WO1995015148A1 Topical preparations containing l-arginine
06/08/1995WO1995013071A3 Treatment of immunoregulatory disorders
06/08/1995WO1995011309A3 A novel nuclear mitotic phosphoprotein: mitosin
06/08/1995CA2617836A1 Nucleosides and oligonucleotides containing boron clusters
06/08/1995CA2178066A1 Dp-iv-serine protease inhibitors
06/08/1995CA2177994A1 Tachykinin antagonists
06/08/1995CA2177991A1 A 46 kd human milk fat globule antigen
06/08/1995CA2177584A1 Antibody against carcinoembryonic antigen (cea)
06/08/1995CA2177570A1 Method of treating intestinal disorders
1 ... 2093 2094 2095 2096 2097 2098 2099 2100 2101 2102 2103 2104 2105 2106 2107 2108 2109 2110 2111 2112 2113 ... 2211